Kraal 2012.

Methods	Multi‐centre pilot study.
Participants	Children with HR NBL.
Interventions	2 cycles of upfront 131I‐MIBG therapy. Of the 33 evaluable children, 16 (48%) received 2 cycles of upfront 131I‐MIBG therapy (group A), 17 (51%) children were treated without upfront 131I‐MIBG therapy (group B; insufficient MIBG uptake, weak clinical condition and hypertension) and 2 children were excluded (they received prior chemotherapy).
Outcomes	131I‐MIBG therapy within 2 weeks from diagnosis was feasible in all children eligible for 131I‐MIBG therapy. Interval between subsequent N5/N6 chemotherapy courses was similar in both groups (22‐30 days). There was no serious haematological toxicity. Stem cell harvest after 131I‐MIBG therapy was undisturbed and did not compromise high‐dose chemotherapy with ASCT treatment. Response analysis (follow‐up 1 January 2005 to 1 January 2012) showed an effect of 2 131I‐MIBG courses in 10/15 (67%) children (1 missing) after 3 times N5/N6 of 15/16 (94%) and at follow‐up of 13/16 (81%).
Notes	This study has not been published in full text (as of 16 May 2016), but was presented at the Advances in Neuroblastoma Research conference 2012.